Additional benefit by share of resolutions

So far, 1174 procedures concerning 515 different medicinal products have been finalised by the G-BA following an early benefit assessment. The decisions entered into force after being published in the Federal Gazette (Bundesanzeiger). On the procedure level, i.e. without taking individual subpopulations into account and using the highest benefit as the basis, the following results can be obtained: According to the G-BA approximately 1.6% of the medicinal products were able to show a major additional benefit and further 15.7% a considerable additional benefit. 15.1% of the assessed products offered a minor additional benefit and 18.8% a non-quantifiable additional benefit. The G-BA found no additional benefit for 47.6% of the innovative medicinal products and for 0.2% less benefit than the appropriate comparative therapy.